Post-authorization changes in the safety and efficacy assessment, recommended indications and drug quality profile of adalimumab: A chronological overview

dc.contributor.author	Iványi, G
dc.contributor.author	Zelkó, Romána
dc.date.accessioned	2019-09-10T16:20:31Z
dc.date.available	2019-09-10T16:20:31Z
dc.date.issued	2017
dc.identifier	85011299943
dc.identifier.citation	journalVolume=55;journalIssueNumber=2;journalTitle=INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS;pagerange=133-137;journalAbbreviatedTitle=INT J CLIN PHARM TH;
dc.identifier.uri	http://repo.lib.semmelweis.hu//handle/123456789/7598
dc.identifier.uri	doi:10.5414/CP202705
dc.format.extent	133-137
dc.title	Post-authorization changes in the safety and efficacy assessment, recommended indications and drug quality profile of adalimumab: A chronological overview
dc.type	Journal Article
dc.date.updated	2019-09-05T20:07:26Z
dc.language.rfc3066	en
dc.rights.holder	NULL
dc.identifier.mtmt	3107985
dc.identifier.wos	000392439100004
dc.identifier.pubmed	27900937
dc.contributor.department	SE/GYTK/Egyetemi Gyógyszertár Gyógyszerügyi Szervezési Intézet
dc.contributor.institution	Semmelweis Egyetem